June 2026 - Page 4 of 4 - BioMedWire (BMW)

WednesdayJun 03, 2026 9:00 am

Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness Markets

Disseminated on behalf of Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) and may include paid advertising. The growing burden of neurological disease has intensified industry-wide interest in therapies capable of protecting neurons, preserving brain function and addressing disease progression at a biological level. Quantum BioPharma’s flagship pharmaceutical subsidiary, Lucid Psycheceuticals Inc., is advancing LUCID-MS, a patented new chemical entity being developed for an unmet need in multiple sclerosis. The company has also expanded its presence in a consumer ready product in the field of alcohol health and sobriety through its involvement with unbuzzd(TM), an innovative, clinically validated alcohol metabolism accelerator designed to…

TuesdayJun 02, 2026 10:00 am

New Inhalable Agent Could Improve Treatment Outcomes in Lung Cancer

A new viral-based vector that can be inhaled into the lungs could boost the anti-cancer response of the body in patients diagnosed with advanced lung cancer. This new treatment could also restore sensitivity to immune checkpoint inhibitors among patients that had become unresponsive. The new investigational therapy, dubbed KB707, was developed by a team at Cleveland Clinic Cancer Institute. The treatment is based on a vector platform leveraging a modified herpes simplex virus that is non-replicating. The agent delivers cytokines IL-12 and IL-2 directly into the lungs once the patient inhales it. This delivery via inhalation helps to get the therapy into the microenvironment of the tumors in the lungs, and the…

MondayJun 01, 2026 9:45 am

Oncotelic Therapeutics Inc. (OTLC) Holds $388M JV Valuation as Pipeline Momentum Builds

Oncotelic Therapeutics maintained the fair value of its 45% GMP Biotechnology JV stake at approximately $388 million in Q1 2026 despite broader biotech market volatility The valuation was supported by an independent ASC 820 Level 3 assessment using discounted cash flow analysis and market comparables These developments reinforce Oncotelic’s partnership-driven model, designed to advance a multi-billion-dollar oncology pipeline while limiting traditional biotech cash burn pressures Oncotelic Therapeutics (OTCQB: OTLC) continues to distinguish itself within a biotechnology sector often characterized by aggressive capital raises and persistent cash burn. In its recently filed first-quarter 2026 financial results, the company maintained the fair value…

MondayJun 01, 2026 9:00 am

How Advanced Drug Delivery Could Improve Existing Cancer Treatments

BioMedWire Editorial Coverage: As oncology drug-development costs continue climbing and regulatory pathways become increasingly complex, biotechnology companies are placing renewed emphasis on improving existing therapeutics through advanced delivery technologies rather than relying exclusively on discovering entirely new drugs. Across the healthcare sector, growing attention is being directed toward nanoparticle delivery systems, intravenous reformulations and precision pharmacokinetic strategies designed to potentially improve bioavailability, systemic exposure, tolerability and dosing consistency of established cancer therapies. Within this broader movement, Oncotelic Therapeutics Inc. (OTCQB: OTLC) (Profile) is advancing its Sapu003 program and Deciparticle(TM) platform as part of a larger industry trend focused on scalable nanotechnology-enabled…